# Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff

> **NCT04320238** · PHASE3 · UNKNOWN · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 2944 (estimated)

## Conditions studied

- 2019 Novel Coronavirus Infection

## Interventions

- **DRUG:** recombinant human interferon Alpha-1b
- **DRUG:** thymosin alpha 1

## Key facts

- **NCT ID:** NCT04320238
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-21
- **Primary completion:** 2020-05
- **Final completion:** 2020-06
- **Target enrollment:** 2944 (ESTIMATED)
- **Last updated:** 2020-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04320238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04320238, "Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04320238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*